Clinical Trial: Calcitonin Gene-related Peptide in Familial Hemiplegic Migraine (FHM) and Migraine With Aura (MA)

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: CGRP-induced Headache in Patients With Familial Hemiplegic Migraine, Migraine With Aura and Healthy Controls

Brief Summary: The aim of the present study is to explore the importance of migraine phenotype on the headache/migraine responses after CGRP in FHM-patients, MA-patients and healthy volunteers.

Detailed Summary:

Calcitonin gene-related peptide (CGRP) induces migraine attacks indistinguishable from spontaneous attacks in a large proportion of migraine sufferers. Treatment of spontaneous migraine attacks with an inhibitor of CGRP is effective in many patients. These data show that CGRP is involved in migraine pathophysiology.

The importance of migraine genetics is disputed. Evidence from FHM patients with known mutations indicates that migraine pathways in FHM may be different from normal migraine. The aim of the present study is to examine whether this difference also exists in FHM patients without known mutations. The project will improve our understanding of the neurobiology of migraine and stimulate development of new treatment targets.

Sponsor: Danish Headache Center

Current Primary Outcome: Migraine and associated symptoms [ Time Frame: 0-14 h ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Migraine aura [ Time Frame: 0 - 14 h ]

Original Secondary Outcome: Same as current

Information By: Danish Headache Center

Dates:
Date Received: May 28, 2008
Date Started: May 2008
Date Completion:
Last Updated: July 31, 2009
Last Verified: July 2009